NCT02960230 - H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 18, 2016

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Diffuse Intrinsic Pontine GliomaGliomaDiffuse Midline Glioma, H3 K27M-Mutant

Interventions

BIOLOGICAL

K27M peptide

K27M peptide vaccine, combined with Tetanus Toxoid peptide, emulsified in montanide. Poly-ICLC will be given concurrently

DRUG

Nivolumab

anti-programmed cell death protein 1 (PD-1) monoclonal antibody

Trial Locations (15)

8032

The University Children's Hospital in Zurich, Zurich

19104

Children's Hospital of Philadelphia, Philadelphia

20010

Children's National Medical Center, Washington D.C.

38105

St. Jude Children's Research Hospital, Memphis

43205

Nationwide Children's Hospital, Columbus

55455

Children's Hospitals and Clinics of Minnesota, Minneapolis

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

63110

St. Louis Children's Hospital, St Louis

77030

Texas Children's Hospital, Houston

84112

University of Utah, Salt Lake City

92123

Rady Children's Hospital-San Diego, San Diego

94158

University of California, San Francisco, San Francisco

97239

Oregon Health & Science University, Portland

98105

Seattle Children's Hospital, Seattle

02215

Dana-Farber Cancer Institute, Boston